U.S. market Open. Closes in 5 hours 22 minutes

EPIX | ESSA Pharma Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 1.7400 - 1.8200
52 Week Range 1.4000 - 11.67
Beta 2.21
Implied Volatility 330.23%
IV Rank 60.01%
Day's Volume 107,097
Average Volume 815,343
Shares Outstanding 44,368,958
Market Cap 78,976,745
Sector Healthcare
Industry Biotechnology
IPO Date 2015-03-13
Valuation
Profitability
Growth
Health
P/E Ratio -2.87
Forward P/E Ratio N/A
EPS -0.62
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 50
Country Canada
Website EPIX
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
EPIX's peers: CLSD, DBVT, CYTO, SMMT, ATXI, SPRO, AGLE, JSPR
*Chart delayed
Analyzing fundamentals for EPIX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is strong. For more detailed analysis please see EPIX Fundamentals page.

Watching at EPIX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on EPIX Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙